Ascletis of Hangzhou and San Francisco’s 3-V Biosciences have started a US-China Phase II clinical trial of their partnered treatment for non-alcoholic steatohepatitis (NASH). Ascletis acquired China rights to TVB-2640/ASC40, a fatty acid synthase (FASN) inhibitor, earlier this year when it led a $18 Series E financing in 3-V Biosciences. The trial will evaluate the candidate in about 90 US NASH and 25-30 China NASH patients. Ascletis focuses on liver diseases with several approved treatments for hepatitis C.
Source: China Biotoday
